Investor Presentaiton

TIRZEPATIDE: SURMOUNT-3 & SURMOUNT-4 TRIALS DEMONSTRATED SIGNIFICANT AND SUPERIOR WEIGHT LOSS COMPARED TO PLACEBO Lilly SURMOUNT-3 SURMOUNT-3 evaluated the efficacy and safety of tirzepatide compared to placebo for 72 weeks after a 12- week intensive lifestyle intervention lead-in period Participants, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% over 84 weeks Safety profile was similar to incretin-based therapies approved for the treatment of obesity and overweight SURMOUNT-4 SURMOUNT-4 evaluated the efficacy and safety of tirzepatide compared to placebo for 52 weeks after a 36- week open-label tirzepatide lead-in period Participants achieved 21.1% mean weight loss during a 36- week tirzepatide lead-in period and an additional 6.7% mean weight loss during a 52-week continued treatment period, for a total mean weight loss of 26.0% over 88 weeks Safety profile was similar to incretin-based therapies approved for the treatment of obesity and overweight Not for promotional use 2023 Q2 EARNINGS 17

View entire presentation